• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDTRONIC IRELAND ENDEAVOR RX; STENT, CORONARY, DRUG-ELUTING

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDTRONIC IRELAND ENDEAVOR RX; STENT, CORONARY, DRUG-ELUTING Back to Search Results
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Myocardial Infarction (1969); Thrombus (2101)
Event Date 03/17/2020
Event Type  Injury  
Manufacturer Narrative
Title: coronary calcification and long-term outcomes according to drug-eluting stent generation authors: paul guedeney, bimmer e.Claessen, roxana mehran, et.Al.Journal: jacc: cardiovascular intervention issue: 12 ref: doi.Org/10.1016/j.Jcin.2020.03.053.Age=average age.Sex= majority gender.Ethnicity= majority race.Date of event=date of publication patient death(s) were also included in the results of the journal article, however no causal link suggesting that the medtronic device(s) used in the patient cohort may have caused or contributed to the death(s) was provided if information is provided in the future, a supplemental report will be issued.
 
Event Description
An article titled "coronary calcification and long-term outcomes according to drug-eluting stent generation" was submitted.The aim of the study was to evaluate the long-term impact of coronary artery calcification (cac) on outcomes after percutaneous coronary intervention and the respective performance of first- and second-generation drug-eluting stents (des).This study was a large patient-level meta-analysis of 18 randomized trials comprising 19,833 patients treated with des.The patients were divided into two groups based on the type of stents they were treated with: first generation des and second generation des.The endeavor rx and resolute integrity rx were among the stents used to treat patients in the second generation des group.Second generation des were used in 11,960 patients.Clinical outcomes were assessed at 5 year follow up.Clinical outcomes included all-cause and cardiac death, myocardial infarction, any revascularization, target lesion revascularization (tlr), target lesion failure and probable or definite stent thrombosis.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ENDEAVOR RX
Type of Device
STENT, CORONARY, DRUG-ELUTING
Manufacturer (Section D)
MEDTRONIC IRELAND
parkmore business park west
galway
IE 
Manufacturer (Section G)
MEDTRONIC IRELAND
parkmore business park west
galway
IE  
Manufacturer Contact
toni o'doherty
parkmore business park west
galway 
IE  
091708734
MDR Report Key10331194
MDR Text Key202337841
Report Number9612164-2020-02748
Device Sequence Number1
Product Code NIQ
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P060033
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type literature
Reporter Occupation Physician
Type of Report Initial
Report Date 07/28/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received07/28/2020
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received07/15/2020
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age63 YR
-
-